345 related articles for article (PubMed ID: 20473155)
1. Pathogenesis of muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies.
Burckart K; Beca S; Urban RJ; Sheffield-Moore M
Curr Opin Clin Nutr Metab Care; 2010 Jul; 13(4):410-6. PubMed ID: 20473155
[TBL] [Abstract][Full Text] [Related]
2. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
Zhou X; Wang JL; Lu J; Song Y; Kwak KS; Jiao Q; Rosenfeld R; Chen Q; Boone T; Simonet WS; Lacey DL; Goldberg AL; Han HQ
Cell; 2010 Aug; 142(4):531-43. PubMed ID: 20723755
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory burden and amino acid metabolism in cancer cachexia.
Durham WJ; Dillon EL; Sheffield-Moore M
Curr Opin Clin Nutr Metab Care; 2009 Jan; 12(1):72-7. PubMed ID: 19057191
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia.
Bowen TS; Adams V; Werner S; Fischer T; Vinke P; Brogger MN; Mangner N; Linke A; Sehr P; Lewis J; Labeit D; Gasch A; Labeit S
J Cachexia Sarcopenia Muscle; 2017 Dec; 8(6):939-953. PubMed ID: 28887874
[TBL] [Abstract][Full Text] [Related]
5. F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.
Sukari A; Muqbil I; Mohammad RM; Philip PA; Azmi AS
Semin Cancer Biol; 2016 Feb; 36():95-104. PubMed ID: 26804424
[TBL] [Abstract][Full Text] [Related]
6. Ghrelin: from discovery to cancer cachexia therapy.
Molfino A; Formiconi A; Rossi Fanelli F; Muscaritoli M
Curr Opin Clin Nutr Metab Care; 2014 Sep; 17(5):471-6. PubMed ID: 24905862
[TBL] [Abstract][Full Text] [Related]
7. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.
Dalton JT; Taylor RP; Mohler ML; Steiner MS
Curr Opin Support Palliat Care; 2013 Dec; 7(4):345-51. PubMed ID: 24189892
[TBL] [Abstract][Full Text] [Related]
8. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment.
Miyamoto Y; Hanna DL; Zhang W; Baba H; Lenz HJ
Clin Cancer Res; 2016 Aug; 22(16):3999-4004. PubMed ID: 27340276
[TBL] [Abstract][Full Text] [Related]
9. Deliberation on debilitating condition of cancer cachexia: Skeletal muscle wasting.
Dave S; Patel BM
Fundam Clin Pharmacol; 2023 Dec; 37(6):1079-1091. PubMed ID: 37474262
[TBL] [Abstract][Full Text] [Related]
10. Mechanism and novel therapeutic approaches to wasting in chronic disease.
Ebner N; Springer J; Kalantar-Zadeh K; Lainscak M; Doehner W; Anker SD; von Haehling S
Maturitas; 2013 Jul; 75(3):199-206. PubMed ID: 23664695
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiology of peripheral muscle wasting in cardiac cachexia.
Filippatos GS; Anker SD; Kremastinos DT
Curr Opin Clin Nutr Metab Care; 2005 May; 8(3):249-54. PubMed ID: 15809526
[TBL] [Abstract][Full Text] [Related]
12. Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia.
Ham DJ; Murphy KT; Chee A; Lynch GS; Koopman R
Clin Nutr; 2014 Jun; 33(3):448-58. PubMed ID: 23835111
[TBL] [Abstract][Full Text] [Related]
13. IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway.
Liu D; Qiao X; Ge Z; Shang Y; Li Y; Wang W; Chen M; Si S; Chen SZ
Skelet Muscle; 2019 Mar; 9(1):8. PubMed ID: 30922397
[TBL] [Abstract][Full Text] [Related]
14. Role of PARP activity in lung cancer-induced cachexia: Effects on muscle oxidative stress, proteolysis, anabolic markers, and phenotype.
Chacon-Cabrera A; Mateu-Jimenez M; Langohr K; Fermoselle C; García-Arumí E; Andreu AL; Yelamos J; Barreiro E
J Cell Physiol; 2017 Dec; 232(12):3744-3761. PubMed ID: 28177129
[TBL] [Abstract][Full Text] [Related]
15. Exercise as an anti-inflammatory therapy for cancer cachexia: a focus on interleukin-6 regulation.
Daou HN
Am J Physiol Regul Integr Comp Physiol; 2020 Feb; 318(2):R296-R310. PubMed ID: 31823669
[TBL] [Abstract][Full Text] [Related]
16. Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia.
Baracos VE
Nutrition; 2000 Oct; 16(10):1015-8. PubMed ID: 11054610
[TBL] [Abstract][Full Text] [Related]
17. Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions.
Siddiqui JA; Pothuraju R; Jain M; Batra SK; Nasser MW
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188359. PubMed ID: 32222610
[TBL] [Abstract][Full Text] [Related]
18. Withaferin A ameliorates ovarian cancer-induced cachexia and proinflammatory signaling.
Straughn AR; Kakar SS
J Ovarian Res; 2019 Nov; 12(1):115. PubMed ID: 31767036
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
20. Advances in pharmacologic strategies for cancer cachexia.
Madeddu C; Mantovani G; Gramignano G; Macciò A
Expert Opin Pharmacother; 2015; 16(14):2163-77. PubMed ID: 26330024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
